1. Home
  2. JFR vs PCRX Comparison

JFR vs PCRX Comparison

Compare JFR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

N/A

Current Price

$7.24

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$36.40

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JFR
PCRX
Founded
2004
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2004
2010

Fundamental Metrics

Financial Performance
Metric
JFR
PCRX
Price
$7.24
$36.40
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
★ $33.57
AVG Volume (30 Days)
904.7K
★ 2.2M
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 11.31%
N/A
EPS Growth
N/A
★ 107.44
EPS
N/A
★ 0.19
Revenue
N/A
★ $541,533,000.00
Revenue This Year
N/A
$3.84
Revenue Next Year
N/A
$4.73
P/E Ratio
★ N/A
$191.47
Revenue Growth
N/A
★ 26.04
52 Week Low
$7.09
$18.80
52 Week High
$8.00
$36.67

Technical Indicators

Market Signals
Indicator
JFR
PCRX
Relative Strength Index (RSI) 45.10 83.12
Support Level $7.23 $21.97
Resistance Level $7.64 $36.67
Average True Range (ATR) 0.09 0.09
MACD 0.01 -0.23
Stochastic Oscillator 44.55 27.40

Price Performance

Historical Comparison
JFR
PCRX

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: